

XESTOQUINONE. A NOVEL CARDIOTONIC MARINE NATURAL PRODUCT  
ISOLATED FROM THE OKINAWAN SEA SPONGE XESTOSPONGIA SAPRA<sup>1)</sup>

Hideshi NAKAMURA,\* Jun'ichi KOBAYASHI, Masaki KOBAYASHI,  
Yasushi OHIZUMI, and Yoshimasa HIRATA<sup>†</sup>

Mitsubishi-Kasei Institute of Life Sciences, 11 Minamiooya,  
Machida, Tokyo 194

<sup>†</sup>Faculty of Pharmacy, Meijo University, Tempaku, Nagoya 468

A new pentacyclic quinone, xestoquinone was isolated from the Okinawan sea sponge Xestospongia sapra as a cardiotonic constituent and the structure was identified from its spectral data.

Recently much attention has been given to bioactive sponge metabolites which have rare functionalities and structural variety.<sup>2)</sup> In the course of our program on physiologically active substances of marine organisms,<sup>3,4)</sup> we examined pharmacological actions of extracts of about 500 species of marine organisms by using isolated muscle preparations. As a result, the extract of the Okinawan sea sponge Xestospongia sapra showed a powerful cardiotonic activity. We followed the activity and obtained the active principle, named xestoquinone (1).




Table 1. Comparison of xestoquinone (1) with halenaquinone (2) in  $^1\text{H}$  NMR

H at	1 <sup>a)</sup>	2 <sup>b)</sup>
C-1	7.62 (t, 1H, J=2 Hz)	8.76 (s, 1H)
C-3	2.68 (dddd, 1H, J=17,10,9,2 Hz) 2.92 (dddd, 1H, J=17,8,3,2 Hz)	
C-4	2.1-2.4 (m, 2H)	2.22 (dd, 1H), 2.94 (dd, 1H)
C-5	1.78 (ddd, J=13,13,5 Hz) 2.59 (ddd, J=13,4,4 Hz)	2.74 (dd, 1H) 3.11 (ddd, 1H)
C-11	9.14 (s, 1H)	8.66 (s, 1H)
C-14,15	7.12 (s, 2H)	7.13 (s, 2H)
C-18	8.32 (s, 1H)	8.28 (s, 1H)
C-20	1.52 (s, 3H)	1.68 (s, 3H)

a) Recorded in  $\text{CDCl}_3$  at 270 MHz.

b) Recorded in  $(\text{CD}_3)_2\text{SO}$  (Ref. 6).

Table 2. Comparison of xestoquinone (1) with halenaquinone (2) in  $^{13}\text{C}$  NMR

Atom	1 <sup>a)</sup>	2 <sup>b)</sup>	1 <sup>a)</sup>	2 <sup>b)</sup>
C-1	146.0 (d) <sup>c)</sup>	150.4 (d)	C-11	124.8 (d) 125.2 (d)
C-2	121.6 (s)	122.1 (s)	C-12	129.9 (s) 129.9(s)
C-3	17.8 (t)	190.9 (s)	C-13	183.8 (s) 183.3 (s)
C-4	16.2 (t)	32.3 (t)	C-14	139.0 (d) 138.7 (d)
C-5	30.3 (t)	36.1 (t)	C-15	139.0 (d) 138.8 (d)
C-6	37.0 (s)	36.4 (s)	C-16	184.2 (s) 183.8 (s)
C-7	142.9 (s)	143.9 (s)	C-17	133.1 (s) 133.3 (s)
C-8	147.8 (s)	147.9 (s)	C-18	122.9 (d) 123.5 (d)
C-9	169.2 (s)	169.5 (s)	C-19	136.8 (s) 136.3 (s)
C-10	155.8 (s)	154.1 (s)	C-20	31.7 (q) 29.7 (q)

a) Recorded in  $(\text{CD}_3)_2\text{SO}$  at 22.5 MHz.

b) Recorded in  $(\text{CD}_3)_2\text{SO}$  at 75.6 MHz (Ref. 6).

c) Multiplicities were determined by off-resonance decoupling techniques.

Collections were made in Kerama Rettō, Okinawa, using SCUBA (-10 ~ -20 m). The benzene soluble portion of methanolic extracts of the fresh sea sponge (3 kg) was chromatographed on a silica gel column with chloroform as eluant by monitoring the cardiotoxic activity using the guinea pig left atria stimulated electrically. The resulted active fraction was further separated by a silica gel column using a 2:3 mixture of ethyl acetate and hexane to afford 20mg of xestoquinone (1) as a yellow powder, mp 212-214 °C (decomposed).<sup>5)</sup>

The molecular formula of C<sub>20</sub>H<sub>14</sub>O<sub>4</sub> was determined by high resolution mass measurements of the molecular ion at m/z 318.0870. The optical rotation value ( $[\alpha]_D^{25} +17.2^\circ$ ,  $c$  1.16, CH<sub>2</sub>Cl<sub>2</sub>) indicated an unsymmetrically fused ring structure. The fused aromatic structure of 1 was identified by interpretation of the spectral data. Comparison of the <sup>1</sup>H NMR data (Table 1) and <sup>13</sup>C NMR data (Table 2) of 1 with those of the known natural compound halenaquinone (2).<sup>6)</sup> indicated that these molecules were identical in the C-6 to C-20 region. In the <sup>1</sup>H NMR spectrum (CDCl<sub>3</sub>) the proton signals of the furan ring in 1 was observed at δ 7.62 (t, 1H, J = 2 Hz), which is in a higher field region than that of 2 (δ 8.76). The furan proton signals couples with the methylene proton signals at δ 2.68 (dddd, 1H, J = 17, 10, 9, 2 Hz) and 2.92 (dddd, 1H, J = 17, 8, 3, 2 Hz), and this suggests that the C-3 position of 1 is a methylene group instead of the carbonyl group in 2. The structure of C-3 to C-5 region was revealed by homonuclear spin decoupling experiments. The absolute configuration of C-6 position is not yet determined.

Xestoquinone (1) showed a marked inotropic action and also caused a concentration-dependent inhibitory effect on the Na,K-ATPase isolated from pig cerebral cortex. Xestoquinone is the first example of marine natural products having parallelism between the inotropic action and Na,K-ATPase inhibition as well as cardiotoxic glycosides.<sup>7-9)</sup> The pharmacological actions of xestoquinone will be reported elsewhere in detail.

We acknowledge Dr. T. Hoshino (Mukaishima Marine Biological Station, Hiroshima University) for his kind identification of the sea sponge, and Mr. T. Hayase and Dr. Ohtani (Central Research Laboratories, Mitsubishi Chemical Industries Ltd.) for  $^1\text{H}$  NMR measurements. We also thank Mr. Z. Nagahama for his assistance of collecting the sea sponge.

#### References

- 1) Physiologically active marine natural product from Porifera VII. Preceding paper: H. Nakamura, J. Kobayashi, Y. Ohizumi, and Y. Hirata, *Tetrahedron Lett.*, 25, 5401 (1984).
- 2) L. Minale, G. Cimino, S. De Stefano, and G. Sodano, *Progress in the Chemistry of Organic Natural Products*, 33, 1 (1976).
- 3) S. Sato, H. Nakamura, Y. Ohizumi, J. Kobayashi, and Y. Hirata, *FEBS Lett.*, 155, 277 (1983).
- 4) H. Wu, H. Nakamura, J. Kobayashi, Y. Ohizumi, and Y. Hirata, *Tetrahedron Lett.*, 25, 3719 (1984).
- 5) **1**: IR( $\text{CHCl}_3$ )  $\nu_{\text{max}}$  2950, 1680, 1610, 1450, 1320  $\text{cm}^{-1}$ ; UV( $\text{CH}_3\text{CN}$ )  $\lambda_{\text{max}}$  217 ( $\epsilon$  14400), 252 (14400), 259 (sh, 13600), 296 (8020), 340 nm (4280).
- 6) **2** has been isolated from the sea sponge *Xestospongia exigua* as an antimicrobial constituent and the structure has been determined by X-ray analysis [D. M. Roll, P. J. Scheuer, G. K. Matsumoto, and J. Clardy, *J. Am. Chem. Soc.*, 105, 6177 (1983)].
- 7) K. S. Lee and W. Klans, *Pharmac. Rev.*, 23, 193 (1971)
- 8) T. Akera, *Science*, 198, 569 (1977).
- 9) T. Akera and T. M. Brody, *Pharmac. Rev.*, 29, 187 (1978).

(Received February 22, 1985)